Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВПО Российский университет дружбы народов, Москва
Список исп. литературыСкрыть список 1. Аведисова А.С. Научные обоснования и практические рекомендации перевода больных с типичных нейролептиков на рисполепт (обзор иностранной литературы). Психиатр. и психофармакотер. 2001; 6: 210–3. 2. Белоусов Ю.Б., Белоусов Д.Ю., Омельяновский В.В. и др. Фармакоэкономическая эффективность атипичных антипсихотиков у больных шизофренией. Психиатр. и психофармакотер. 2007; 4. 3. Данилов Д.С. Влияние поддерживающей психофармакотерапии на качество жизни больных шизофренией с приступообразным течением. Автореф. дис. … канд. мед. наук. М., 2005. 4. Дэвис Д.М. Шизофрения: выбор антипсихотической терапии. Соц. и клин. психиатрия. 2006; 3: 77–80. 5. Иванов С.В. Улучшение комплаентности больных шизофренией к терапии антипсихотиками. Психиатр. и психофармакотер. 2008; 3: 27–9. 6. Любов Е.Б., Чапурин С.А., Чурилин Ю.Ю. Фармакоэкономическая модель антирецидивного лечения Сероквелем, Рисполептом и Зипрексой пациентов в первом эпизоде шизофрении. Психиатр. и психофармакотер. 2005; 4: 193–8. 7. Мазаева Н.А. Риски и преимущества применения атипичных антипсихотиков в психиатрии (по данным зарубежных публикаций последних лет). Психиатр. и психофармакотер. 2006; 5: 4–11. 8. Медведев В.Э. Негативные расстройства: понятие и терапия. Психиатр. и психофармакотер. 2011; 6: 16–21. 9. Медведев В.Э. Амдоал (арипипразол) при длительной терапии шизофрении. Дневник психиатра. 2013; 1: 17–9. 10. Медведев В.Э. Оланзапин в психиатрической практике. Психиатр. и психофармакотер. 2011; 5: 10–5. 11. Мосолов С.Н. Современная антипсихотическая фармакотерапия шизофрении. Рус. мед. журн. 2004; 10: 6. 12. Мосолов С.Н., Калинин В.В., Еремин А.В. Сравнительная эффективность и переносимость нового поколения антипсихотических средств при лечении обострений шизофрении. Новые достижения в терапии психических заболеваний. М.: Бином, 2002; с. 82–94. 13. Мосолов С.Н. Полвека нейролептической терапии: основные итоги и новые рубежи. Новые достижения в терапии психических заболеваний. М., 2002. 14. Попов М.Ю. Общие принципы выбора антипсихотического препарата при терапии шизофрении. Обозрение психиатрии и мед. психологии им. В.М.Бехтерева. 2006; 4: 1–14. 15. Снедков Е.В. Атипичные антипсихотики: поиск решения старых и новых проблем. Психиатр. и психофармакотер. 2006; 4: 45–50. 16. Сыропятов О.Г. Современное лечение шизофрении. Нейронауки. 2007; 2. 17. Цыганков Б.Д., Агасарян Э.Т. Анализ эффективности и безопасности современных и классических антипсихотических препаратов. Журн. неврол. и психиатр. 2010; 9: 64–70. 18. Addington DE, Jones B, Bloom D et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917–26. 19. Ananth J, Parameswaran S, Gunatilake S et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiat 2004; 65 (4): 464–70. 20. Angermeyer M, Matschinger H. Neuroleptics and quality of life. A patient survey. Psychiatr Prax 2000; 27 (2): 64–8. 21. Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiat 1997; 42: 233–46. 22. Ascher-Svanum H, Nyhuis AW, Stauffer V et al. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Current Med Research Opin 2010; 10: 2403–10. 23. Ashok K, Ross M, Norman P et al. Early signs in schizophrenia spectrum disorders. Cl Therapeutics 1999; 21 (5): 806–17. 24. Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders: Antipsychotic and antimanic agents. In: J.Hardman, L.Limbird, A.Gilman (eds.). Goodman and Gilman’s the pharmacological basis of therapeutics. 10th ed. NY: McGraw-Hill Press 2001; pp. 485–528. 25. Bartko G, Varadi H, Simon L et al. Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia. Int J Psychiat Clin Pract 2002; 6: 9–14. 26. Beasley CM, Tollefson G, Tran P et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol 1996; 14: 111–23. 27. Beasley CM, Dellva MA, Tamura RN et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiat 1999; 174: 23–30. 28. Bodkin JA, Siris SG, Bermanzohn PC et al. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiat 2005; 162: 388–90. 29. Borison R. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing. Cl Therapeutics 1996; 18 (4): 666–83. 30. Chengappa KN, Goldstein JM, Greenwood M et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003; 25: 530–41. 31. Daniel DG, Goldberg TE, Weinberger DR et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiat 1996; 153: 417–9. 32. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiat 2003; 60: 553–64. 33. De Nayer A, Windhager E, Irmansyah F et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiat Clin Pract 2003; 7: 59–66. 34. Desai NM, Haq Z, Martin SD et al. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Advanc Ther 1999; 16 (2): 78–88. 35. Dwight MM, Keck PE, Stanton SP et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 1994; 344: 554–5. 36. Ganesan S, Agambaram V, Randeree F et al. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res 2008; 24 (1): 21–32. 37. Garman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Cl Psychopharm 1995; 10: 207–13. 38. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6. 39. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiat 1994; 55 (9): 107–9. 40. Goldberg TE, Weinberger DR. The effects of clozapine on neurocognition: an overview. J Clin Psychiat 1994; 55: 88–90. 41. Green MF, Marshall BD, Wirshing WC et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiat 1997; 154: 799–804. 42. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64: 2291–314. 43. Hamman J, Leucht S, Kissling W. Are the Second-Generation Antipsychotics Cost-effecrive? A Critical Review on the Background of Different Health Systems. Pharmacopsychiat 2003; 36: 18–26. 44. Hennen J, Perlis RH, Sachs G et al. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiat 2004; 65: 1679–87. 45. Heres S, Davis J, Maino K et al. Why olanzapine beats risperidone, risperidone beats quetiapine and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiat 2006; 163: 185–94. 46. Hoff AL, Riordan H, O’Donnell DW et al. Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiat 1992; 149: 898–902. 47. Kabinoff GS, Toalson PA, Healey KM et al. Metabolic issues with atypical antipsychotics in primary care: Dispelling the Myths. J Clin Psychiat 2003; 5 (1): 6–14. 48. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. Psychopharmacol Suppl 1985; 2: 72–8. 49. Kerwin R. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiat 1994; 164: 141–8. 50. Kirov GK, Murray RM et al. Observations on switching patients with schizophrenia to risperidone treatment. Risperidone Switching Study Group. Acta Psych Scand 1997; 95: 439–43. 51. Kleinberg DL, Davis JM, de Coster R et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19: 57–61. 52. Leucht S, Barnes TR, Kissling W et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiat 2003; 160: 1209–22. 53. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68. 54. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics vs low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581–9. 55. Littrell K, Jones-Vaughn JE, MacFariane J. Соблюдение режима лечения в психиатрии: что должен знать каждый врач, лечащий больных шизофренией (реферат). Психиатр. и психофармакотер. 2005; 4: 23–7. 56. Markovic O, Goyvaerts H, Beuzen JN. Cognitive benefits of aripiprazole vs olanzapine in stable psychoses. World J Biol Psychiat 2005; 6 (Suppl. 1): 265. 57. Marder HL. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Drug Development 1994; 6 (4): 153–7. 58. Margolese HC, Chouinard G, Kolivakis TT et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathp ophysiology and mechanisms of induction. Can J Psychiat 2005; 50 (9): 541–7. 59. Mаrеr SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia. J Clin Psychiat 1997; 58: 538–46. 60. Masand PS. Olanzapine versus other antipsychotics in the treatment of schizophrenia. J Clin Psychiat 2001; 62 (10): 828–9. 61. McGurk SR, Coleman T, Harvey PD et al. Working memory performance in poor outcome schizophrenia: relationship to age and executive functioning. J Clin Exp Neuropsychol 2004; 26 (2): 153–60. 62. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. J Schizophr 2000; 13 (2): 33–5. 63. Meltzer H. Dimensions of outcome with clozapine. Br J Psychiat 1992; 160 (Suppl. 17): 46–53. 64. Meltzer HY. Mechanism of action of atypical antipsychotic drugs. In: K.Davis, D.Charney, J.Coyle, C.Nemeroff (eds.). Neuropsychopharmacology: the fifth generation of progress. Philadelphia: Lippincott Williams & Wilkins 2002; p. 819–33. 65. Palia SS, Clarke EJ. Neuroleptic malignant syndrome in hyperemesis gravidarum. Psychiatr Bull 1993; 17: 374–5. 66. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiat 2002; 63: 1121–8. 67. Ritchie CW, Harrigan S, Mastwyk M et al. Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3 1/2 years duration. Int J Geriat Psychiat 2010; 25: 411–8. 68. Rosenheck RA. Effectiveness vs efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiat Serv 2005; 56: 85–92. 69. Saltz BL, Kane JM, Woerner MG et al. Prospective study of tardive dyskinesia in the elderly. Psychopharmacol Bull 1989; 25: 52–6. 70. Saltz BL, Woerner MG, Kane JM et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402–6. 71. Sharma T, Kerwin R. Biological determinants of difficult to treat patients with schizophrenia. Br J Psychiat Suppl 1996; 31: 5–9. 72. Sinus SG. Depression and schizophrenia. In: S.Hirsch D.Weinhorder (eds). Schizophrenia. London: Blackwell Science Publications 1995; 128–45. 73. Straus SM et al. Antipsychotics and risk of sudden cardiac death. Arch Intern Med 2004; 164; 1293–7. 74. Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, risperidone and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiat 2006; 163: 611–22. 75. Kim Sung-Wan et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 2009; 32 (5): 243–9. 76. Taylor DM, McAskill R. Atypical antipsychotics and weight gain – a systematic review. Acta Psychiat Scand 2000; 101: 416–32. 77. Thakore JH. Metabolic syndrome and schizophrenia. Br J Psychiat 2005; 186: 455–6. 78. Umbricht DS, Kane JM. Understanding the Relationship between Extrapyramidal Side Effects and Tardive Dyskinesia in Serotonin in Antipsychotic Treatment. Ed.: J.Kane, H-J.Muller, F.Awouters Y.: Marcel Dekker Inc., 1996. 79. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomized antipsychotic drug trials. Psychopharmacol (Berl) 2001; 155: 230–3. 80. Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiat 1997; 58 (Suppl. 10): 63–72. 81. Woerner MG, Kane JM, Lieberman JA et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991; 11: 34–42.